GlassScriptPhysician profile
Geetika Gupta
NPI 1669801619
$6,450.32
in general payments reported to CMS, 2019-2025
44 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,471 · 2020: $810 · 2021: $1,727 · 2022: $324 · 2023: $246 · 2024: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,117.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,006.09 | 2019-2024 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $808.35 | 2019-2024 | Rybelsus, Ozempic, Sogroya |
| Sanofi-Aventis U.S. LLC | $541.61 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $481.53 | 2019-2022 | |
| Amgen INC. | $372.03 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $355.78 | 2019-2024 | Unithroid |
| Abbvie INC. | $282.64 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.48 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $209.13 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $201.48 | 2019-2021 | |
| Medtronic, INC. | $183.61 | 2021-2024 | Minimed 780g |
| Ibsa Pharma INC. | $170.96 | 2019-2023 | Licart, Tirosint |
| Radius Health, INC. | $119.58 | 2019-2024 | Tymlos |
| Ipsen Biopharmaceuticals, INC | $107.93 | 2019-2022 | |
| Insulet Corporation | $106.76 | 2019-2020 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Geetika Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.